Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP769201.RAhC116XVcdWM7tqcAdmQyl_J2nr-R9Qvxh6gZUfLfgp8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP769201.RAhC116XVcdWM7tqcAdmQyl_J2nr-R9Qvxh6gZUfLfgp8130_assertion type Assertion NP769201.RAhC116XVcdWM7tqcAdmQyl_J2nr-R9Qvxh6gZUfLfgp8130_head.
- NP769201.RAhC116XVcdWM7tqcAdmQyl_J2nr-R9Qvxh6gZUfLfgp8130_assertion description "[Reducing the number of weekly treatments per cycle from four to three and adding prophylactic dexamethasone, which abrogated interleukin-6 release and CRS (P < or = .01), resulted in improved tolerability and treatment delivery.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP769201.RAhC116XVcdWM7tqcAdmQyl_J2nr-R9Qvxh6gZUfLfgp8130_provenance.
- NP769201.RAhC116XVcdWM7tqcAdmQyl_J2nr-R9Qvxh6gZUfLfgp8130_assertion evidence source_evidence_literature NP769201.RAhC116XVcdWM7tqcAdmQyl_J2nr-R9Qvxh6gZUfLfgp8130_provenance.
- NP769201.RAhC116XVcdWM7tqcAdmQyl_J2nr-R9Qvxh6gZUfLfgp8130_assertion SIO_000772 19826119 NP769201.RAhC116XVcdWM7tqcAdmQyl_J2nr-R9Qvxh6gZUfLfgp8130_provenance.
- NP769201.RAhC116XVcdWM7tqcAdmQyl_J2nr-R9Qvxh6gZUfLfgp8130_assertion wasDerivedFrom befree-2016 NP769201.RAhC116XVcdWM7tqcAdmQyl_J2nr-R9Qvxh6gZUfLfgp8130_provenance.
- NP769201.RAhC116XVcdWM7tqcAdmQyl_J2nr-R9Qvxh6gZUfLfgp8130_assertion wasGeneratedBy ECO_0000203 NP769201.RAhC116XVcdWM7tqcAdmQyl_J2nr-R9Qvxh6gZUfLfgp8130_provenance.